The involvement of microglia in Alzheimer's disease: a new dog in the fight

Abstract

First described clinically in 1906, Alzheimer's disease (AD) is the most common neurodegenerative disease and form of dementia worldwide. Despite its prevalence, only five therapies are currently approved for AD, all dealing with the symptoms rather than the underlying causes of the disease. A multitude of experimental evidence has suggested that the once thought inconsequential process of neuroinflammation does, in fact, contribute to the AD pathogenesis. One such CNS cell type critical to this process are microglia. Plastic in nature with varied roles, microglia are emerging as key contributors to AD pathology. This review will focus on the role of microglia in the neuroinflammatory response in AD, highlighting recent studies implicating aberrant changes in microglial function in disease progression. Of critical note is that with these advances, a reconceptualization of the framework in which we view microglia is required. Linked Articles This article is part of a themed section on Therapeutics for Dementia and Alzheimer's Disease: New Directions for Precision Medicine. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.18/issuetoc

Antioxidant Nanoparticles for Concerted Inhibition of α-Synuclein Fibrillization, and Attenuation of Microglial Intracellular Aggregation and Activation

“…As previously discussed, rather than focusing on neurons as a pharmacological target, microglia could serve as a more upstream cellular target of interest in PD since microglia are involved in αSYN trafficking, aggregation, and clearance, and are closely associated with the triggers for the neuroinflammation process (Ferreira and Romero-Ramos, 2018;Moore et al, 2018;Xia et al, 2019). Further investigation into how antioxidantbased composite NPs may influence αSYN transmission among microglia and other CNS cells, especially neurons, would provide valuable insight into the interplay between different CNS cell types in the trafficking and aggregation of αSYN and its related pathology.…”

“…Microglial activation is one of the main neuroinflammatory mechanisms that contributes to neuronal degeneration, as shown by post-mortem and in vivo studies in PD (Hirsch and Hunot, 2009;Moore et al, 2018). Release of pro-inflammatory cytokines and reactive free radicals such as tumor necrosis factor (TNFα), interleukin-6 (IL-6) nitric oxide (NO), reactive oxygen species (ROS) and extracellular vesicles containing toxic protein aggregates resulting from microglial activation can lead to the degeneration and death of neighboring healthy neurons, particularly DA neurons (Hoenen et al, 2016;Subramaniam and Federoff, 2017).…”

The Potential Role of Herpes Simplex Virus Type 1 and Neuroinflammation in the Pathogenesis of Alzheimer's Disease

“…Astrocyte dysfunction has been shown to result in an increase of pro-inflammatory mediators release, decrease of glutamate uptake, loss of synapses, and ultimately cognitive deficits in AD ( 124 ). A number of recent reviews further examine particular aspects of the role of microglia and astrocytes in the neuroinflammatory response in AD, including phenotypical and functional changes, genetic variants of the innate microglial immune receptor TREM2, which has been associated with an increased risk of LOAD ( 105 , 125 – 129 ).…”

Brain Metabolism Alterations in Type 2 Diabetes: What Did We Learn From Diet-Induced Diabetes Models?

“…Damage of synapses is the most important step for brain dysfunction (Morrison and Baxter, 2012), and the degree of synaptic changes correlates with the severity of cognitive decline (Sheng et al, 2012). Synaptic dysfunction and neurotoxicity in age-associated dementia and AD are mainly caused by amyloid plaques, but also neuroinflammation with reactive microglia (Moore et al, 2019). Mitochondria are also involved in synaptic degeneration due to compromised ATP synthesis (energy failure), as well as impaired Ca 2+ handling, increased production of reactive oxygen species (ROS), impaired production of metabolites that are neurotransmitter precursors, and dysregulation of mitochondrial dynamics and mitochondriadependent cell signaling transduction (Tait and Green, 2012;Guo et al, 2017;Belenguer et al, 2019).…”